Description
Human papillomavirus (HPV) infection, particularly type 16, is associated with the development of cervical cancer. The constitutively expressed HPV principal transforming protein E7 makes an attractive target for T cell based immunotherapy. One of the E7 peptides, HPV E711-20 (YMLDLQPETT), has been identified as one of the epitopes for CD8+ T cells detected in individuals with cervical cancer. IGNYTE BIO offers CD8+ T cells specific for HPV E711-20 (YMLDLQPETT) in association with HLA-A*0201. Antigen-specificity is demonstrated by tetramer binding as well as functional studies (specific IFN-gamma release and cytotoxicity)